Celts welcome Celgene’s Patient access scheme for Vidaza, too
This article was originally published in Scrip
Executive Summary
Celgene has finally secured a recommendation in Scotland for its bone marrow drug Vidaza (5-azacitidine) for treating myelodysplastic syndrome and leukaemia with a patient access scheme. The company eventually won a recommendation in England with the same tactic.